



### Trokendi XR® (topiramate) – Expanded Indication

- On August 18, 2016, the [FDA approved](#) Supernus Pharmaceuticals' [Trokendi XR \(topiramate\)](#) extended-release capsules in patients  $\geq 6$  years of age as initial monotherapy for partial onset or primary generalized tonic-clonic seizures. Safety and effectiveness in patients who were converted to monotherapy from a previous regimen of other anticonvulsant drugs have not been established in controlled trials.
  - Previously, Trokendi XR was indicated as initial monotherapy in patients  $\geq 10$  years of age with partial onset or primary generalized tonic-clonic seizures and adjunctive therapy in patients  $\geq 6$  years of age with partial onset or primary generalized tonic-clonic seizures.
- Trokendi XR is also approved as adjunctive therapy in patients  $\geq 6$  years of age with partial onset seizures, primary generalized tonic-clonic seizures, and seizures associated with Lennox-Gastaut syndrome.
- The expanded indication is based on a pharmacokinetic study which demonstrated similarity of exposure-response in pediatric patients and adults when topiramate was given as initial monotherapy.
- The recommended dose of Trokendi XR as initial monotherapy in patients 6 -- 10 years of age for partial onset or primary generalized tonic-clonic seizures is 25 mg once daily at night for the first week. Based on tolerability, the dose is titrated over 5 -- 7 weeks. Total daily doses are weight-based.
  - Trokendi XR should be swallowed whole and intact. It should not be sprinkled on food, chewed or crushed.
  - Refer to the prescribing information for dosing recommendations for all other labeled indications.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

Rx News® is published by the OptumRx Clinical Services Department.

©2016 Optum, Inc. All rights reserved.